Do analysts rate INCR or KPTI?

Karyopharm Therapeutics has a consensus target price of $17.17, indicating a potential upside of 75.71%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is INCR or KPTI more profitable?

InterCure has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Karyopharm Therapeutics -129.02% N/A -120.29%

Do analysts recommend INCR or WHWK?

Whitehawk Therapeutics has a consensus price target of $8.00, indicating a potential upside of 74.67%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is INCR or WHWK more profitable?

InterCure's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Whitehawk Therapeutics N/A -79.63% -74.01%

Is SGMT or INCR more profitable?

InterCure's return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% InterCure N/A N/A N/A

Do analysts prefer INCR or SLGL?

Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 166.39%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts prefer INCR or LENZ?

LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 425.11%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

InterCure (INCR) Competitors

$1.10 +0.06 (+5.94%)

Closing price 06/30/2026 03:59 PM Eastern

Extended Trading

$1.07 -0.03 (-3.09%)

As of 06/30/2026 07:07 PM Eastern

Compare

INCR vs. KPTI, WHWK, SGMT, SLGL, and LENZ

Should you buy InterCure stock or one of its competitors? MarketBeat compares InterCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InterCure include Karyopharm Therapeutics (KPTI), Whitehawk Therapeutics (WHWK), Sagimet Biosciences (SGMT), Sol-Gel Technologies (SLGL), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.

How does InterCure compare to Karyopharm Therapeutics?

InterCure (NASDAQ:INCR) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

InterCure has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

8.3% of InterCure shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, InterCure and InterCure both had 2 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.94 beat InterCure's score of 0.44 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Karyopharm Therapeutics	Positive

Karyopharm Therapeutics has a consensus target price of $17.17, indicating a potential upside of 75.71%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

InterCure has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.77	-$10.37M	$0.03	36.67
Karyopharm Therapeutics	$146.07M	1.52	-$196.04M	-$15.09	N/A

InterCure has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats InterCure on 9 of the 15 factors compared between the two stocks.

How does InterCure compare to Whitehawk Therapeutics?

InterCure (NASDAQ:INCR) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 2 mentions for InterCure. Whitehawk Therapeutics' average media sentiment score of 0.96 beat InterCure's score of 0.44 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Whitehawk Therapeutics	Positive

InterCure has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.77	-$10.37M	$0.03	36.67
Whitehawk Therapeutics	$7.14M	31.72	-$20.60M	-$1.68	N/A

InterCure has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

8.3% of InterCure shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Whitehawk Therapeutics has a consensus price target of $8.00, indicating a potential upside of 74.67%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Whitehawk Therapeutics beats InterCure on 8 of the 15 factors compared between the two stocks.

How does InterCure compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Sagimet Biosciences has a beta of 3.41, suggesting that its share price is 241% more volatile than the broader market. Comparatively, InterCure has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

InterCure's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
InterCure	N/A	N/A	N/A

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 2 articles in the media. Sagimet Biosciences' average media sentiment score of 0.94 beat InterCure's score of 0.44 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sagimet Biosciences	Positive
InterCure	Neutral

InterCure has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	125.92	-$51.04M	-$1.34	N/A
InterCure	$78.47M	0.77	-$10.37M	$0.03	36.67

Sagimet Biosciences currently has a consensus target price of $25.57, indicating a potential upside of 230.81%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sagimet Biosciences is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sagimet Biosciences beats InterCure on 8 of the 14 factors compared between the two stocks.

How does InterCure compare to Sol-Gel Technologies?

InterCure (NASDAQ:INCR) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

8.3% of InterCure shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 166.39%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sol-Gel Technologies has lower revenue, but higher earnings than InterCure. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.77	-$10.37M	$0.03	36.67
Sol-Gel Technologies	$19.39M	10.74	-$6.13M	-$0.34	N/A

InterCure has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

InterCure has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. InterCure's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

In the previous week, Sol-Gel Technologies had 1 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 2 mentions for InterCure. Sol-Gel Technologies' average media sentiment score of 0.72 beat InterCure's score of 0.44 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Sol-Gel Technologies	Positive

Summary

Sol-Gel Technologies beats InterCure on 10 of the 17 factors compared between the two stocks.

How does InterCure compare to LENZ Therapeutics?

InterCure (NASDAQ:INCR) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

InterCure has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. InterCure's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

8.3% of InterCure shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InterCure has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.77	-$10.37M	$0.03	36.67
LENZ Therapeutics	$19.09M	9.32	-$82.13M	-$3.60	N/A

LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 425.11%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, LENZ Therapeutics had 3 more articles in the media than InterCure. MarketBeat recorded 5 mentions for LENZ Therapeutics and 2 mentions for InterCure. LENZ Therapeutics' average media sentiment score of 1.01 beat InterCure's score of 0.44 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
LENZ Therapeutics	Positive

InterCure has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Summary

InterCure and LENZ Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.78M	$8.64B	$7.07B	$12.45B
Dividend Yield	N/A	2.52%	2.66%	6.16%
P/E Ratio	36.67	15.85	27.25	24.87
Price / Sales	0.77	7.22	540.68	102.84
Price / Cash	N/A	17.76	48.53	58.59
Price / Book	0.52	3.42	11.01	6.54
Net Income	-$10.37M	$226.25M	$3.57B	$336.70M
7 Day Performance	10.00%	1.32%	2.31%	2.88%
1 Month Performance	2.80%	-3.33%	1.39%	0.64%
1 Year Performance	-25.68%	3.81%	36.71%	31.34%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	0.6925 of 5 stars	$1.10 +5.9%	N/A	-25.2%	$56.78M	$78.47M	36.67	350	Short Interest Increase Gap Up
KPTI Karyopharm Therapeutics	2.2719 of 5 stars	$9.40 +3.3%	$17.17 +82.6%	+126.7%	$206.23M	$146.07M	N/A	380
WHWK Whitehawk Therapeutics	3.1578 of 5 stars	$4.22 +1.2%	$7.33 +73.8%	+144.9%	$206.22M	$7.14M	N/A	21	News Coverage Gap Down High Trading Volume
SGMT Sagimet Biosciences	2.9909 of 5 stars	$6.53 +3.7%	$25.57 +291.6%	+1.4%	$205.29M	$2M	N/A	8
SLGL Sol-Gel Technologies	3.8236 of 5 stars	$70.36 -3.4%	$110.00 +56.3%	+901.9%	$204.76M	$19.39M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. KPTI, WHWK, SGMT, SLGL, and LENZ

How does InterCure compare to Karyopharm Therapeutics?

Summary

How does InterCure compare to Whitehawk Therapeutics?

Summary

How does InterCure compare to Sagimet Biosciences?

Summary

How does InterCure compare to Sol-Gel Technologies?

Summary

How does InterCure compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. KPTI, WHWK, SGMT, SLGL, and LENZ

How does InterCure compare to Karyopharm Therapeutics?

Is INCR or KPTI more profitable?

Do insiders and institutionals have more ownership in INCR or KPTI?

Does the media prefer INCR or KPTI?

Do analysts rate INCR or KPTI?

Which has preferable valuation & earnings, INCR or KPTI?

Which has more risk and volatility, INCR or KPTI?

Summary

How does InterCure compare to Whitehawk Therapeutics?

Does the media favor INCR or WHWK?

Which has better valuation & earnings, INCR or WHWK?

Which has more volatility & risk, INCR or WHWK?

Do institutionals & insiders have more ownership in INCR or WHWK?

Is INCR or WHWK more profitable?

Do analysts recommend INCR or WHWK?

Summary

How does InterCure compare to Sagimet Biosciences?

Which has more volatility and risk, SGMT or INCR?

Is SGMT or INCR more profitable?

Does the media refer more to SGMT or INCR?

Which has higher earnings & valuation, SGMT or INCR?

Do analysts prefer SGMT or INCR?

Do insiders and institutionals believe in SGMT or INCR?

Summary

How does InterCure compare to Sol-Gel Technologies?

Do institutionals and insiders believe in INCR or SLGL?

Do analysts prefer INCR or SLGL?

Which has higher valuation and earnings, INCR or SLGL?

Which has more risk and volatility, INCR or SLGL?

Is INCR or SLGL more profitable?

Does the media favor INCR or SLGL?

Summary

How does InterCure compare to LENZ Therapeutics?

Is INCR or LENZ more profitable?

Do insiders & institutionals hold more shares of INCR or LENZ?

Which has stronger earnings and valuation, INCR or LENZ?

Do analysts prefer INCR or LENZ?

Does the media prefer INCR or LENZ?

Which has more volatility & risk, INCR or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools